China's Tianyin Pharma faces NYSE de-listing on failure to file quarterly report

SINGAPORE--China's Tianyin Pharmaceutical ($TPI) may be in danger of being de-listed from the New York Stock Exchange for failing to file its latest quarterly report on time. The company said it has until mid-March to respond.

Until TPI presents a plan of complying with NYSE rules, it will be listed as in non-compliance, it said. The latest quarterly filing overdue covers the quarter ending Dec. 31.

In a notice, the company said it was working hard with its auditor to complete its quarterly report and disseminate it as required, adding it expected to meet the March 10 deadline for a response.

- read the release